Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy
James R. Berenson(Oncotherapeutics (United States)), Howard Yeh(Hospital de Santa Maria)
Cited by 57
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
|Journal of Clinical Oncology|2000|383
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
|Supportive Care in Cancer|2013|182
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
|Clinical Cancer Research|2007|123
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
|Journal of Bone and Mineral Research|2009|120